Drug treatment of acute infective exacerbations of COPD;Tratamiento farmacológico de las agudizaciones infecciosas de la EPOC

Archivos de Bronconeumologia

Volumn 43, Issue SUPPL.4, 2007, Pages 18-26

  Miravitlles, Marc ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Antibiotics; COPD; Exacerbations; Infection; Treatment

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; IMMUNOFERON; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ERADICATION THERAPY; HUMAN; INFECTION; LUNG FUNCTION; NONHUMAN; OUTPATIENT CARE; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; VIRUS INFECTION;

EID: 46749103738     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/s0300-2896(07)74006-1     Document Type: Review

References (63)

1. Miravitlles M, Morera J. It's time for an etiology-based definition of chronic obstructive pulmonary disease. Respirology. 2007;12:317-9.
2. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114-21.
3. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
4. Vestbo J. What is an exacerbation of COPD? Eur Respir Rev. 2004;13:6-13.
5. Van der Valk P, Monninkhof E, Van der Palen J, Zielhuis G, Van Herwaarden C, Hendrix R. Clinical predictors of bacterial involvement in exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis. 2004;39:980-6.
6. Hurst JR, Donaldson GC, Perera WR, Wilkinson TMA, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:867-74.
7. Van der Meer V, Neven AK, Van der Broek PJ, Assendelft WJJ. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ. 2005;331:26-31.
8. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600-7.
9. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117:1638-45.
10. Soler N, Agustí C, Angrill J, Puig de la Bellacasa J, Torres A. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax. 2007;62:29-35.
11. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function. Chest. 1998;113:1542-8.
12. Miravitlles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M, and Study Group of Bacterial Infection in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40-6.
13. Allegra L, Blasi F, Diano PL, Cosentini R, Tarsia P, Confalonieri M, et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med. 2005;99:742-7.
14. Rosell A, Monsó E, Soler N, Torres F, Angrill J, Riise G, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med. 2005;165:891-7.
15. Monsó E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med. 1995;152:1316-20.
16. Patel S, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57:759-64.
17. 1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:1090-5.
18. Donaldson GC, Seemungal TAR, Bhomik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847-52.
19. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347:465-71.
20. Wilson R, Dowling RB, Jackson AD. The biology of bacterial colonisation and invasion of the respiratory mucosa. Eur Respir J. 1996;9:1646-52.
21. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J. 2002;20 Suppl 36:9-19.
22. Chodosh S, Schreurs A, Siami G, Barkman HW Jr, Anzueto A, Shan M, et al. The efficacy of oral ciprofloxacin vs. clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis. 1998;27:730-8.
23. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest. 2005;127:2231-6.
24. Wilson R, Allegra L, Huchon G, Izquierdo JL, Jones P, Schaberg T, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004;125:953-64.
25. Sethi S, Wrona C, Grant BJ, Murphy TF. Strain specific response to Haemophilus influenzae in chronic obstructuve pulmonary disease. Am J Respir Crit Care Med. 2004;169:448-53.
26. Miravitlles M. Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med. 2002;9:191-7.
27. Seemungal TAR, Harpe-Owen R, Bhowmik A, Jeffries DJ, Wedzicha JA. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J. 2000;16:677-83.
28. Wilkinson TMA, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest. 2006;129:317-24.
29. Monsó E, García-Aymerich J, Soler N, Farrero E, Félez MA, Antó JM, et al. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect. 2003;131:799-804.
30. Miravitlles M, Murio C, Guerrero T on behalf of the DAFNE Study Group. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the community. Eur Respir J. 2001;17:928-33.
31. Martínez FJ, Anzueto A. Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Am J Med. 2005;118:395-445.
32. Miravitlles M. Health status and costs of exacerbations of chronic bronchitis and COPD: how to improve antibiotic treatment. Expert Rev Pharmacoeconomics Outcomes Res. 2005;5:423-35.
33. Thornsberry C, Sahm DF. Antimicrobial resistance in respiratory tract pathogens: results of an international surveillance study. Chemotherapy. 2000;46 Suppl 1:15-23.
34. García JA, Baquero F, García J, Aguilar L. Antimicrobial susceptibility of 1,422 Haemophilus influenzae isolates from respiratory tract infections in Spain. Results of a 1-year (1996-97) multicenter surveillance study. Spanish Surveillance Group for Respiratory Pathogens. Infection. 1999;27:265-7.
35. Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L, Nicolau F, Segú JL on behalf of the EOLO Group. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration. 2000;67:495-501.
36. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest. 2000;117:1345-52.
37. García-Aymerich J, Barreiro E, Farrero E, Marrades RM, Morera J, Antó JM. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J. 2000;16:1037-42.
38. Blasi F, Tarsia P, Aliberti S, Santus PA, Allegra L. Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. Pulm Pharmacol Ther. 2006;19:11-9.
39. Miravitlles M. Moxifloxacin in respiratory tract infections. Expert Opin Pharmacother. 2005;6:283-93.
40. Niederman MS, Anzueto A, Sethi S, Choudhri S, Kureishi A, Haverstock D, et al. Eradication of H. influenzae in AECB: a pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir Med. 2006;100:1781-90.
41. Miravitlles M, Martín Graczyk A. Tratamiento del paciente con EPOC agudizada. En: SEPAR-SEGG (Sociedad Española de Geriatría y Gerontología), editores. Guía de buena práctica clínica en geriatría: enfermedad pulmonar obstructiva crónica. Madrid: Elsevier Farma; 2006. p. 75-88.
42. Wilson R, Jones P, Schaberg T, Arvis P, Duprat-Lomon I, Sagnier PP. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax. 2006;61:337-42.
43. Lode H, Eller J, Linnhoff A, Ioanas M. Levofloxacin versus clarithromycin in COPD exacerbations: focus on exacerbation-free interval. Eur Respir J. 2004;24:947-53.
44. Miravitlles M, Zalacain R, Murio C, Álvarez-Sala JL, Masa JF, Verea H, et al, on behalf of the IMPAC study group. Speed of recovery from acute exacerbations of COPD after treatment with antimicrobials: results of a two-year study. Clin Drug Invest. 2003;23:439-50.
45. Álvarez-Sala JL, Kardos P, Martínez-Beltrán J, Coronel P, Aguilar L, and the Cefditoren AECB Working Group. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother. 2006;50:1762-7.
46. Sethi S, Breton J, Wynne B. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother. 2005;49:153-60.
47. Gil VF, Payá MA, Asension MA, Torres MT, Pastor R, Merino J. Incumplimiento del tratamiento con antibióticos en infecciones agudas no graves. Med Clin (Barc). 1999;112:731-3.
48. Martínez FJ, Grossman RF, Zadeikis N, Fisher AC, Walker K, Ambruzs ME, et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J. 2005;25:1001-10.
49. Martínez FJ. Acute exacerbation of chronic bronchitis: expanding short-course therapy. Int J Antimicrob Agents. 2005;26 Suppl 3:156-63.
50. Wilkinson TMA, Donaldson GC, Hurst JR, Seemungal TAR, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonay disease. Am J Respir Crit Care Med. 2004;169:1298-303.
51. Miravitlles M, Ferrer M, Pont A, Zalacain R, Álvarez-Sala JL, Masa JF, et al. Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A two-year follow-up study. Thorax. 2004;59:387-95.
52. Miravitlles M, Calle M, Álvarez-Gutiérrez F, Gobartt E, López F, Martín A, and the EIME group. Exacerbations, hospital admissions and impaired health status in chronic obstructive pulmonary disease. Qual Life Res. 2006;15:471-80.
53. Miravitlles M, Anzueto A, Legnani D, Forstmeier L, Fargel M. Patient's perception of exacerbations of COPD - the PERCEIVE study. Respir Med. 2007;101:453-60.
54. Scott S, Walker P, Calverley PMA. COPD exacerbations. 4: prevention. Thorax. 2006;61:440-7.
55. Arandjus C, Black PN, Poole PJ, Baker RW, Steuere-Stey C. Oral bacterial vaccines for the prevention of acute exacerbations in chronic obstructive pulmonary disease and chronic bronchitis. Respir Med. 2006;100:1671-81.
56. Alfageme I, Vazquez R, Reyes N, Muñoz J, Fernández A, Hernandez M, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax. 2006;61:189-95.
57. British Thoracic Society. Chronic obstructive pulmonary disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Managing stable COPD. Thorax. 2004;59 Suppl 1:39-130.
58. Prieto A, Reyes E, Bernstein ED, Martínez B, Montserrat J, Izquierdo JL, et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (Inmunoferon). Am J Respir Crit Care Med. 2001;163:1578-83.
59. Reyes E, Prieto A, De la Hera A, De Lucas P, Álvarez-Sala R, Álvarez-Sala JL, et al. Treatment with AM3 restores defective T-cell function in COPD patients. Chest. 2006;129;527-35.
60. Álvarez-Mon M, Miravitlles M, Morera J, Callol L, Álvarez-Sala JL. Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest. 2005;127:1212-8.
61. Staykova T, Black P, Chacko E, Ram FSF, Poole P. Prophylactic antibiotic therapy for chronic bronchitis (Cochrane Review). En: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
62. Sethi S, Anzueto A, Wilson R, Jones PW, Wedzicha JA, Miravitlles M, et al. Placebo-controlled, double-blind trial of chronic, intermittent pulse therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data. Eur Respir J. 2006;28 Suppl 50:842.
63. De Benedetto F, Sevieri G. Chronic obstructive pulmonary disease (COPD) exacerbation and inflammation of the respiratory tract: clinical implication, prognostic consequences, and therapeutic strategies. Multidisciplinary Respiratory Medicine. 2006;1:36-48.